Eli Lilly and CompanyLLY

Tenth-place with 1,027% return (10.27x), driven by blockbuster diabetes/obesity drugs and 43% YoY revenue growth. Receives minimum 2% allocation as the only non-tech holding, providing modest sector diversification at the tail.